Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.

Boursier J, Hagström H, Ekstedt M, Moreau C, Bonacci M, Cure S, Ampuero J, Nasr P, Tallab L, Canivet CM, Kechagias S, Sánchez Y, Dincuff E, Lucena A, Roux M, Riou J, Trylesinski A, Romero-Gomez M. J Hepatol. 2022 Jan 18:S0168-8278(22)00002-2. doi: 10.1016/j.jhep.2021.12.031.